Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgPro20 in Post-COVID-19 POTS
NCT06524739Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of IgPro20 in postural orthostatic tachycardia syndrome (POTS), sponsored by CSL Limited. Started Aug 2024; status: terminated.
02
Drugs
IgPro20
03
Conditions
postural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT06524739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524739.